Cantargia
3.79 SEK -0.26%1,317 investors are following this company
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
3.724 / 3.972
SEK
Market cap
696.17M SEK
Turnover
583.69K SEK
Volume
154K
Latest videos
Financial calendar
Interim report
2024-08-28
Interim report
2024-11-15
Annual report
2025-02-21
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.9 % | 9.9 % |
Första AP-Fonden | 7.1 % | 7.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Cantargia reports organisational change
Cantargias presenterar kliniska fas II-resultat i bukspottkörtelcancer med nadunolimab på ESMO Gastrointestinal Cancer Congress 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools